What changed
$HCA — ADD 📊
🎯 Q1 FY26 | Rev $19B | EPS $7.15 vs $7.13 🟢
💡 Consensus expects HCA to face headwinds from labor costs and softer volume growth, but Q1 showed 22% operating cash flow growth, strong FCF conversion, and aggressive buybacks reducing share count by 9% YoY. The market is underestimating the earnings power from capital allocation and operational leverage.
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 15% to $430 (12x forward EBITDA) vs downside 10% to $337 (10x forward EBITDA); ratio 1.5:1.
🔮 Catalyst: Continued buyback execution and Q2 earnings (late July 2026); watch for same-facility admission growth >1% and FCF >$900M; failure signal: admission growth turns negative or buybacks slow materially.
Also in play: $UHS $THC $CYH $HCA $SGRY $BDX